Jia Jie Biomedical Co., Ltd. (4109) AI Stock Analysis

Jia Jie Biomedical Co., Ltd.

(TPEx:4109)

Select Model

Rating:50Neutral

Price Target:TWD 10.00▼(-2.44% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by deteriorating profitability and negative free cash flow, despite a very strong low-debt balance sheet. Weak technical momentum and an exceptionally high P/E ratio further reduce the overall score.

Positive Factors

Conservative Balance SheetVery low leverage and substantial equity growth provide financial resilience and reduce the burden of debt service. This gives Jia Jie greater flexibility to absorb operating volatility, preserve liquidity, and support future investment without relying heavily on external financing.

Negative Factors

Weak Cash ConversionWeak conversion of reported earnings into operating cash reduces confidence in earnings quality and limits internally generated funding. Negative free cash flow in 2025 also suggests that spending or working-capital demands could continue to constrain liquidity and capital allocation.

Jia Jie Biomedical Co., Ltd. (4109) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.21B
Dividend Yield: 1.95%
Average Volume (3M): 135.49K
Price to Earnings (P/E): 256.3
Beta (1Y): 0.38
Revenue Growth: 13.00%
EPS Growth: 902.22%
Country: TW
Employees: 67
Sector: General
Sector Strength: 55
Industry: Packaged Foods

Jia Jie Biomedical Co., Ltd. Business Overview & Revenue Model

Company Description

Jia Jie Biomedical Co., Ltd., headquartered in Kaohsiung, Taiwan, was established in 1995. Formerly known as Murad Chia Jei Biotechnology Co., Ltd. until its rebranding in June 2019, the company primarily specializes in the production and distributio...

Jia Jie Biomedical Co., Ltd. Financial Statement Overview

Summary

Strong balance sheet and very low leverage are offset by sharply weaker profitability, declining margins, lower return on equity, and negative free cash flow.

Income Statement

43Neutral

Balance Sheet

88Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	514.65M	485.40M	537.07M	332.76M	317.72M	242.48M
Gross Profit	137.84M	150.34M	173.35M	117.64M	116.51M	83.77M
EBITDA	60.57M	18.24M	241.93M	161.30M	12.12M	18.58M
Net Income	4.17M	50.26M	211.37M	144.15M	-5.47M	5.34M
Balance Sheet
Total Assets	1.88B	1.89B	1.48B	1.41B	1.00B	1.02B
Cash, Cash Equivalents and Short-Term Investments	500.33M	481.56M	263.05M	384.17M	253.75M	286.31M
Total Debt	87.85M	52.96M	8.78M	76.75M	3.73M	5.27M
Total Liabilities	223.60M	174.89M	123.08M	342.69M	80.00M	86.47M
Stockholders Equity	1.62B	1.68B	1.33B	1.05B	897.98M	907.87M
Cash Flow
Free Cash Flow	-52.35M	-64.15M	24.72M	-13.10M	-26.64M	2.85M
Operating Cash Flow	13.04M	21.34M	44.35M	-4.49M	-8.78M	4.37M
Investing Cash Flow	-121.67M	-186.12M	-128.15M	2.55M	-35.02M	-173.05M
Financing Cash Flow	28.78M	348.51M	-158.77M	234.57M	-3.73M	-2.48M

Jia Jie Biomedical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4109 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6846	55Neutral	TWD 1.33B	12.56	―	8.05%	-3.09%	-27.22%
TW:4109	50Neutral	TWD 1.21B	256.25	―	1.95%	13.00%	902.22%
TW:4133	48Neutral	TWD 1.20B	27.03	―	0.56%	-4.19%	―

* General Sector Average

Performance Comparison

TW:4109 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4109	Jia Jie Biomedical Co., Ltd.	10.25	-5.51	-34.96%
TW:4133	Abnova Taiwan Corp.	20.00	-3.47	-14.79%
TW:6564	Enimmune corporation	14.90	-6.22	-29.44%
TW:6677	Anxo Pharmaceutical Co., Ltd.	20.95	-2.35	-10.09%
TW:6846	Greenyn Biotechnology Co., Ltd.	49.00	-23.75	-32.65%
TW:7814	Horien Biochemical Technology Co., Ltd.	27.30	-11.35	-29.37%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Jia Jie Biomedical Co., Ltd. AI Stock Analysis